Skip to main content
Clinical Trials/NL-OMON36226
NL-OMON36226
Recruiting
Phase 2

MR-guided focal laser ablation of the prostate: a pilot study - MR-guided focal laser ablation

niversitair Medisch Centrum Sint Radboud0 sites30 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
prostate cancer
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
30
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria counting for both groups:
  • Newly diagnosed and biopsy proven prostate cancer
  • Low risk patients (PSA \<\= 10 ng/mL, Gleason 3\+3, cT1c \- T2a)
  • No previous treatment for prostate cancer
  • Cancer lesion located at least 2 cm away from the neurovascular bundle
  • according to Multimodality MR images
  • Signed informed consent by patient
  • Age 18 years or older
  • Signed screening form (to determine exclusion for metal device/foreign bodies/claustrophobia);Additional inclusion criterion for patients in group A:
  • Patients must be scheduled for a radical prostatectomy with a lesion of max 4 cm

Exclusion Criteria

  • Impossibility to obtain a valid informed consent
  • Patients unable to undergo MR imaging, including those with contra\-indications
  • Contra\-indications to MR guided focal laser therapy (colitis ulcerosa, rectal pathology or abdomino perineal resection)
  • Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging
  • Patients with evidence for nodal or metastatic disease
  • Patients with an estimated Glomerular Filtration Ratio (eGFR) \< 40 mL/min/1\.73 m2

Outcomes

Primary Outcomes

Not specified

Similar Trials